ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 006,57
0,87%
Dow Jones
38 730,29
0,05%
DAX
18 574,53
0,85%
Brent Oil
77,66
0,71%
Bitcoin
71 550,76
1,31%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Castle Biosciences Inc (CSTL)

  7. Castle Biosciences Inc (CSTL) Actualités

CSTL

Castle Biosciences (CSTL)

Castle Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CSTL
DateHeureSourceTitreSymboleSociété
05/06/202400h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
30/05/202422h30Business WireCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceNASDAQ:CSTLCastle Biosciences Inc
29/05/202422h30Business WireNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisNASDAQ:CSTLCastle Biosciences Inc
24/05/202422h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CSTLCastle Biosciences Inc
15/05/202413h00Business WireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceNASDAQ:CSTLCastle Biosciences Inc
14/05/202413h00Business WireCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024NASDAQ:CSTLCastle Biosciences Inc
10/05/202421h14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CSTLCastle Biosciences Inc
10/05/202413h00Business WireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”NASDAQ:CSTLCastle Biosciences Inc
08/05/202422h30Business WireLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultNASDAQ:CSTLCastle Biosciences Inc
03/05/202413h00Business WireDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckNASDAQ:CSTLCastle Biosciences Inc
02/05/202422h05Business WireCastle Biosciences Reports First Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
30/04/202422h30Business WireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaNASDAQ:CSTLCastle Biosciences Inc
11/04/202413h00Business WireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024NASDAQ:CSTLCastle Biosciences Inc
10/04/202423h00Business WireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsNASDAQ:CSTLCastle Biosciences Inc
10/04/202413h00Business WireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
04/04/202422h30Business WirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerNASDAQ:CSTLCastle Biosciences Inc
02/04/202413h00Business WireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CSTLCastle Biosciences Inc
27/03/202422h00Business WireCastle Biosciences Announces Updates to its Board of DirectorsNASDAQ:CSTLCastle Biosciences Inc
25/03/202412h00Business WireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
22/03/202421h30Business WireLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBNASDAQ:CSTLCastle Biosciences Inc
19/03/202412h00Business WireLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyNASDAQ:CSTLCastle Biosciences Inc
15/03/202421h30Business WireNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderNASDAQ:CSTLCastle Biosciences Inc
12/03/202412h00Business WireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor ForumNASDAQ:CSTLCastle Biosciences Inc
08/03/202422h30Business WireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CSTLCastle Biosciences Inc
07/03/202413h00Business WireIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk SubgroupsNASDAQ:CSTLCastle Biosciences Inc
28/02/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CSTLCastle Biosciences Inc
28/02/202422h05Business WireCastle Biosciences Reports Fourth Quarter and Full-Year 2023 ResultsNASDAQ:CSTLCastle Biosciences Inc
26/02/202413h00Business WireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition StagingNASDAQ:CSTLCastle Biosciences Inc
07/02/202413h00Business WireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024NASDAQ:CSTLCastle Biosciences Inc
18/01/202413h00Business WireNew Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell CarcinomaNASDAQ:CSTLCastle Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:CSTL

Dernières Valeurs Consultées

NASDAQ
JIVE
JP Morgan International ...
EU
SSB3D
Euronext S BNP 030323 GR...
LSE
BK51
Gemgart.23-1 73
BIT
P1V6G0
NLBNPIT1V6G0 20991231 49...
BIT
P1ZBT6
NLBNPIT1ZBT6 20240621 4.2
TSX
2656
Vector
NASDAQ
KRBP
Kiromic BioPharma
BIT
P1SZT0
NLBNPIT1SZT0 20241220 22
ASX
AQXDE
Alice Queen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés